0000000001024791

AUTHOR

L Punzi

showing 4 related works from this author

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…

2012

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…

Malerheumatoid arthritisArthritisReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidAdalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis FactorsRheumatoidadalimumabMonoclonalReceptorsImmunology and AllergyRegistriesinfectionsHumanizedAnti-TNF agents; GISEA register; Infections; Predictive factorsIncidence (epidemiology)IncidenceAntibodies MonoclonalAnti-TNF agentsMiddle AgedRheumatoid arthritisAntirheumatic AgentsCohortTumor Necrosis FactorsFemaleInfectionPredictive factorsmedicine.druganti-TNF; serious infections; rheumatoid arthritisAdultmedicine.medical_specialtyanti-TNF therapy; infections; rheumatoid arthritis; adalimumab; etanercept; infliximabanti-TNF therapyserious infectionsImmunologyInfections rheumatoid arthritis anti-TNF therapyAntibodies Monoclonal HumanizedInfectionsAntibodiesInternal medicinemedicineAdalimumabHumansAgedGISEA registerbusiness.industryArthritisAdalimumabanti-TNFGISEA register; Infections; Anti-TNF agents; Predictive factors; Adalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis Factorsmedicine.diseaseInfliximabInfliximabConcomitantImmunoglobulin GImmunologyTumor Necrosis Factor InhibitorsbusinessTumor Necrosis Factorinfliximabetanercept
researchProduct

Multi-language translation and cross-cultural adaptation of the OARSI/OMERACT measure of intermittent and constant osteoarthritis pain (ICOAP).

2009

Summary Aim To conduct a multi-language translation and cross-cultural adaptation of the Intermittent and Constant OsteoArthritis Pain (ICOAP) questionnaire for hip and knee osteoarthritis (OA). Methods The questionnaires were translated and cross-culturally adapted in parallel, using a common protocol, into the following languages: Czech, Dutch, French (France), German, Italian, Norwegian, Spanish (Castillan), North and Central American Spanish, Swedish. The process was conducted following five steps: (1) – independent translation into the target language by two or three persons; (2) – consensus meeting to obtain a single preliminary translated version; (3) – backward translation by an ind…

CzechCross-Cultural Comparisonmedicine.medical_specialtyBiomedical EngineeringMEDLINEOsteoarthritisNorwegianKnee – Pain – ICOAP – TranslationOsteoarthritis HipGermanConstant (computer programming)Hip – osteoarthritisRheumatologySurveys and QuestionnairesOsteoarthritismedicineCross-culturalHumansOrthopedics and Sports MedicineTranslationsLanguagePain Measurementbusiness.industryOsteoarthritis Kneemedicine.diseaseCross-cultural studieslanguage.human_languagelanguagePhysical therapybusinessOsteoarthritis and cartilage
researchProduct

Factors associated with the orthopaedic surgeon's decision to recommend total joint replacement in hip and knee osteoarthritis: an international cros…

2018

Summary Objective To determine factors associated with orthopaedic surgeons' decision to recommend total joint replacement (TJR) in people with knee and hip osteoarthritis (OA). Design Cross-sectional study in eleven countries. For consecutive outpatients with definite hip or knee OA consulting an orthopaedic surgeon, the surgeon's indication of TJR was collected, as well as patients' characteristics including comorbidities and social situation, OA symptom duration, pain, stiffness and function (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]), joint-specific quality of life, Osteoarthritis Research Society International (OARSI) joint space narrowing (JSN) radiographi…

MaleCross-sectional studymedicine.medical_treatmentArthroplasty Replacement HipOsteoarthritisappropriatenessSeverity of Illness IndexOsteoarthritis Hip0302 clinical medicineQuality of lifeperspectivespainOrthopedics and Sports Medicine030212 general & internal medicineProspective StudiesArthroplasty Replacement Kneeprimary-careOsteoarthritis Knee3. Good health[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemFemalemusculoskeletal diseasesmedicine.medical_specialtyWOMACDecision MakingBiomedical Engineering03 medical and health sciencesRheumatologyinequalitiesOsteoarthritisSeverity of illnessmedicineHumansKneeneedTotal joint replacementAged030203 arthritis & rheumatologydiseaseHipcriteriabusiness.industryOdds ratioOrthopedic Surgeonsmedicine.diseaseArthroplastyRadiographypredictorsCross-Sectional StudiesOrthopedic surgeryPhysical therapyQuality of LifearthroplastySurgerybusinessOsteoarthritis and cartilage
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct